Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05317078
Registration number
NCT05317078
Ethics application status
Date submitted
30/03/2022
Date registered
7/04/2022
Date last updated
11/01/2024
Titles & IDs
Public title
A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications
Query!
Scientific title
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Participants With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications
Query!
Secondary ID [1]
0
0
20210007
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-squamous Non-small Cell Lung Cancer
0
0
Query!
Epithelial Ovarian Cancer
0
0
Query!
Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Cancer
0
0
0
0
Query!
Ovarian and primary peritoneal
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - AMG 794
Experimental: Part 1: AMG 794 Monotherapy Dose Exploration - Participants with claudin 6 (CLDN6)-positive advanced/metastatic non-squamous non-small cell lung cancer (NSCLC), epithelial ovarian cancer (EOC), or other solid tumor indications will be treated in up to 11 multiple ascending cohorts with additional participants optionally enrolled in dose exploration cohorts with target dose levels that have previously been shown to be safe and tolerable.
Experimental: Part 2: AMG 794 Monotherapy Dose Expansion - Participants with CLDN6-positive advanced/metastatic NSCLC, EOC, or other solid tumor indications will be treated with the OBD of AMG 794 identified in Part 1.
Treatment: Drugs: AMG 794
Short-term intravenous (IV) infusion.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants Who Experience a Dose Limiting Toxicity (DLT)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Day 1 to Day 28
Query!
Primary outcome [2]
0
0
Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
Query!
Assessment method [2]
0
0
Adverse events (AEs) are defined as any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests that occur after study treatment administration will be recorded as TEAEs.
Query!
Timepoint [2]
0
0
Day 1 to a maximum of 2 years
Query!
Primary outcome [3]
0
0
Number of Participants Who Experience a Treatment-related AE
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Day 1 to a maximum of 2 years
Query!
Secondary outcome [1]
0
0
Minimum Efficacious Dose (MED)
Query!
Assessment method [1]
0
0
Defined as the first unconfirmed partial response (PR) or better.
Query!
Timepoint [1]
0
0
Day 1 to a maximum of 2 years
Query!
Secondary outcome [2]
0
0
Maximum Observed Serum Concentration (Cmax) of AMG 794
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Cycle 1 Day 1 to Cycle 6 Day 1 (28 day cycle length)
Query!
Secondary outcome [3]
0
0
Minimum Observed Serum Concentration (Cmin) of AMG 794
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Cycle 1 Day 1 to Cycle 6 Day 1 (28 day cycle length)
Query!
Secondary outcome [4]
0
0
Area Under the Concentration-time Curve (AUC) Over the Dosing Interval of AMG 794
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Cycle 1 Day 1 to Cycle 6 Day 1 (28 day cycle length)
Query!
Secondary outcome [5]
0
0
Confirmed objective response (OR)
Query!
Assessment method [5]
0
0
Defined as best overall response [BOR] of complete response [CR] or PR based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
Query!
Timepoint [5]
0
0
Day 1 to a maximum of 2 years
Query!
Secondary outcome [6]
0
0
Confirmed OR
Query!
Assessment method [6]
0
0
Defined as immune BOR (iBOR) of immune CR (iCR) or immune PR (iPR) based on Immune RECIST (iRECIST).
Query!
Timepoint [6]
0
0
Day 1 to a maximum of 2 years
Query!
Secondary outcome [7]
0
0
Cancer Antigen (CA) 125 Response
Query!
Assessment method [7]
0
0
CA 125 response will be analyzed in the Ovarian Cancer Analysis Set, defined as all participants with a primary tumor type of ovarian cancer who are enrolled and receive at least 1 dose of AMG 794.
Query!
Timepoint [7]
0
0
Day 1 to a maximum of 2 years
Query!
Secondary outcome [8]
0
0
Duration of Response
Query!
Assessment method [8]
0
0
Defined as the time from the first documentation of OR until the first documentation of disease progression or death due to any cause, whichever occurs first.
Query!
Timepoint [8]
0
0
Day 1 to a maximum of 2 years
Query!
Secondary outcome [9]
0
0
Time to Progression
Query!
Assessment method [9]
0
0
Defined as the time from enrollment until the first documentation of radiological disease progression.
Query!
Timepoint [9]
0
0
Day 1 to a maximum of 2 years
Query!
Secondary outcome [10]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [10]
0
0
Defined as the time from enrollment until the first documentation of radiologic disease progression or death due to any cause, whichever occurs first.
Query!
Timepoint [10]
0
0
Day 1 to a maximum of 2 years
Query!
Secondary outcome [11]
0
0
1-year Overall Survival (OS)
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
1 year
Query!
Secondary outcome [12]
0
0
2-year OS
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
2 years
Query!
Eligibility
Key inclusion criteria
Pre-screening:
- Age = 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 -1.
- Participants with histologically or cytologically documented malignant solid tumor
diseases expressing claudin-6 (CLDN6) including but not limited to NSCLC, EOC,
testicular germ cell cancer, uterine endometrial cancer, or triple negative breast
cancer, and the cancer is at least either locally advanced or metastatic at
pre-screening.
- Participant has provided informed consent prior to initiation of any study specific
activities/procedures.
Main study:
- Age = 18 years.
- Participant has provided informed consent prior to initiation of any study specific
activities/procedures.
- ECOG performance status of 0 to 1.
- Participants with histologically or cytologically documented malignant solid tumor
diseases expressing CLDN6 including but not limited to NSCLC, EOC, testicular germ
cell cancer, uterine endometrial cancer, or triple negative breast cancer, that is
metastatic or unresectable at screening time point. Participants should have exhausted
available SOC systemic therapy or should not be candidates for such available therapy.
- For participants enrolling in cohort 3 or higher dose cohort, available positive test
result for CLDN6 expression resulting from testing of an available archival tissue
sample in pre-screening or obtained from biopsy in a screening procedure. For
participants enrolling in cohorts 1, 1a, or 2 during dose escalation, consent to
provide archival or fresh tumor tissue slides for immunohistochemistry (IHC)
assessment is sufficient and the enrolment is not dependent on availability of the
CLDN6 expression test result.
- For dose expansion cohorts: Participants with at least 1 measurable lesion = 10mm
which has not undergone biopsy within 3 months of screening scan. This lesion cannot
be biopsied at any time during the study.
- Life expectancy > 3 months.
- Adequate organ functions.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Main study:
- Positive test for human immunodeficiency virus, hepatitis B or hepatitis C.
- History of other malignancy within the past 2 years.
- Participant with symptoms and/or clinical signs and/or radiographic signs that
indicate an acute and/or uncontrolled active systemic infection with 1 week prior to
administration of a first dose of study treatment
- Evidence of new or growing central nervous system metastases, leptomeningeal disease,
or spinal cord compression. Participants with known brain metastases may be eligible
if they completed radiotherapy, surgery or stereotactic surgery for the brain
metastases and do not present with neurological symptoms and/or have stable disease
assessed by imaging within 4 weeks of signing consent to this study and not requiring
acute corticosteroid therapy or steroid taper.
- Currently receiving treatment in another investigational device or drug study, or less
than 4 weeks since ending treatment on another investigational device or drug
study(ies). Other investigational procedures while participating in this study are
excluded.
- Anticancer therapies including radiotherapy, chemotherapy or molecularly targeted
treatments or tyrosine kinase inhibitors within 2 weeks or 5 half-lives (whichever is
longer) of administration of a first dose of study treatment;
immunotherapies/monoclonal antibodies within 3 weeks of administration of a first dose
of study treatment.
- Has had a major surgery within 4 weeks of administration of a first dose of study
treatment (excluded: biopsies and central venous catheter insertion).
- Autoimmune disorders requiring chronic systemic steroid therapy or any other form of
immunosuppressive therapy while on study, (e.g., ulcerative colitis, Crohn's disease).
Recent or current use of inhaled steroids or physiological substitution in case of
adrenal insufficiency is not exclusionary.
- Female participants who are of childbearing potential unwilling to use
protocol-specified method of contraception, who are breastfeeding and/or planning to
become pregnant.
- Male participants who have a female partner of childbearing potential who are
unwilling to practice sexual abstinence or use protocol-specified contraception and/or
who are unwilling to abstain from donating sperm.
- Participant has known sensitivity to any of the products or components to be
administered during dosing.
- Participant likely to not be available to complete all protocol-required study visits
or procedures, and/or to comply with all required study procedures (e.g., Clinical
Outcome Assessments) to the best of the participant and investigator's knowledge.
- History or evidence of any other clinically significant disorder, condition or disease
(with the exception of those outlined above) that, in the opinion of the investigator
or Amgen physician, if consulted, would pose a risk to participant safety or interfere
with the study evaluation, procedures or completion.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/02/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
23/02/2028
Query!
Actual
Query!
Sample size
Target
98
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA,VIC
Query!
Recruitment hospital [1]
0
0
Southern Oncology Clinical Research Unit - Bedford Park
Query!
Recruitment hospital [2]
0
0
Monash Medical Centre - Clayton
Query!
Recruitment hospital [3]
0
0
Cabrini Hospital - Malvern
Query!
Recruitment postcode(s) [1]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [2]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [3]
0
0
3144 - Malvern
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Virginia
Query!
Country [3]
0
0
Switzerland
Query!
State/province [3]
0
0
Bern
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objectives of this study are to evaluate the safety and tolerability of AMG 794
in adult participants and to determine the optimal biological active dose (OBD), at or below
the maximum tolerated dose (MTD) with MTD 1 as the maximum tolerated starting dose and MTD 2
as the maximum tolerated target dose.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05317078
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05317078
Download to PDF